Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

PURPOSE: Modified gemcitabine and S-1 (GS) is an active regimen for patients with advanced biliary tract cancer (ABTC) in our previous study. Herein, we report the results of a single-arm phase II of nivolumab plus modified GS (NGS) as first-line treatment in ABTC. PATIENTS AND METHODS: Patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Nai-Jung, Tan, Kien Thiam, Bai, Li-Yuan, Hsiao, Chin-Fu, Huang, Chung-Yu, Hung, Yi-Ping, Huang, Chien-Jui, Chen, San-Chi, Shan, Yan-Shen, Chao, Yee, Huang, Yi-Hsiang, Lee, I-Cheng, Lee, Pei-Chang, Su, Yung-Yeh, Chen, Shu-Jen, Yeh, Chun-Nan, Chen, Li-Tzong, Chen, Ming-Huang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527499/
https://www.ncbi.nlm.nih.gov/pubmed/35849151
http://dx.doi.org/10.1158/1078-0432.CCR-22-1152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527499/
https://www.ncbi.nlm.nih.gov/pubmed/35849151
http://dx.doi.org/10.1158/1078-0432.CCR-22-1152

Ejemplares similares